ORIGENE TECHNOLOGIES, INC.

Origene Technologies, Inc. specializes in the manufacturing and research of biological products, with deep expertise in the development, handling, and supply of complex biological materials for federal applications. The company’s technical capabilities center on Good Manufacturing Practice (GMP)-aligned production of non-diagnostic biological agents, including process development, aseptic handling, and cold-chain logistics for sensitive biologics. Their R&D work in biotechnology focuses on translational workflows that bridge laboratory-scale innovation with scalable, regulatory-compliant manufacturing, demonstrating proficiency in molecular biology techniques, bioprocessing, and quality control systems aligned with FDA and NIH standards. Origene differentiates itself through precision in material integrity preservation and end-to-end chain-of-custody protocols for high-value biological assets. The contractor maintains a consistent relationship with the Department of Health and Human Services, delivering critical biological materials and supporting biotechnology research initiatives under HHS oversight. Their work supports public health infrastructure, including research programs requiring controlled biological reagents and validated supply chains for therapeutic or diagnostic precursor materials. Origene operates primarily within NAICS 325414 (Biological Product Manufacturing) and 541711 (Biotechnology R&D), positioning itself at the intersection of production and innovation in the life sciences sector. The company serves niche markets requiring compliant, small-batch manufacturing of non-diagnostic biologics and early-stage research support, often for government-funded biomedical programs. As a small business structured as a 2L entity based in Rockville, Maryland, Origene Technologies is strategically located within the National Institutes of Health corridor, enabling close collaboration with federal research institutions. The company holds no formal government certifications but leverages its technical rigor and regulatory awareness to meet stringent federal biomanufacturing requirements. Its geographic footprint is focused on the Washington, D.C. metro area, aligning with federal biodefense and public health priorities.